# Scribe Therapeutics

**Source:** https://geo.sig.ai/brands/scribe-therapeutics  
**Vertical:** BioTech  
**Subcategory:** CRISPR Epigenetic Gene Silencing (Cardiovascular)  
**Tier:** Emerging  
**Website:** scribetx.com  
**Last Updated:** 2026-04-14

## Summary

Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9 silencing via CasX-ELXR) IND projected mid-2026 — no permanent DNA edits.

## Company Overview

Scribe Therapeutics was co-founded by Jennifer Doudna — who shared the 2020 Nobel Prize in Chemistry for CRISPR-Cas9 invention — and develops the ELXR platform: a CasX-based epigenetic silencing system that reduces gene expression without making permanent DNA cuts. The company has raised $100 million in Series B financing with strategic partnerships with Sanofi and Eli Lilly. The lead program, STX-1150, targets PCSK9 for durable LDL-C reduction and is projected to receive an IND and enter human trials in mid-2026.

The epigenetic silencing approach is ELXR's primary clinical safety differentiator from CRISPR gene editing: rather than cutting and permanently altering DNA (which CRISPR-Cas9 does), ELXR uses CasX to recruit epigenetic machinery that methylates the target gene's promoter — silencing transcription without changing the genetic sequence. This approach is potentially reversible and avoids the permanent off-target editing risks that regulatory agencies scrutinize most carefully in gene editing clinical trials.

PCSK9 inhibition is one of the most commercially validated mechanisms in cardiovascular medicine: Repatha (evolocumab) and Praluent (alirocumab) generate $2+ billion annually. A one-time epigenetic silencing that achieves equivalent LDL-C reduction without monthly injection could transform the $2+ billion injectable PCSK9 market into a one-time treatment.

## Frequently Asked Questions

### What does Scribe Therapeutics do?
ELXR CasX-based epigenetic gene silencing — reduces gene expression by methylating promoters without DNA cuts, reversible unlike CRISPR gene editing. STX-1150 targets PCSK9 for cardiovascular disease.

### How much has Scribe raised?
$100M Series B. Co-founded by Jennifer Doudna (Nobel Prize, CRISPR inventor). Sanofi and Eli Lilly partnerships.

### How is epigenetic silencing different from CRISPR editing?
CRISPR-Cas9 cuts DNA permanently. ELXR methylates gene promoters to silence transcription without altering genetic sequence — potentially reversible and avoiding permanent off-target editing risks.

### What is the PCSK9 commercial opportunity?
Repatha and Praluent (injectable PCSK9 inhibitors) generate $2B+ annually. A one-time epigenetic treatment achieving equivalent LDL reduction could transform the market from monthly injections to a single treatment.

### What is CRISPR epigenetic silencing and how is it different from standard CRISPR editing?
Standard CRISPR-Cas9 creates double-strand DNA breaks to knock out gene function — permanent but associated with DNA repair errors and off-target cuts. CRISPR epigenetic silencing uses a catalytically inactive Cas9 (dCas9) fused to epigenetic modifiers (KRAB repressors, DNA methyltransferases) to silence gene expression without cutting DNA. The silencing is durable — lasting years — but theoretically reversible and avoids DNA damage associated with nuclease activity.

### What is the PCSK9 program and commercial opportunity?
Scribe's lead cardiovascular program targets PCSK9 — the liver protein that degrades LDL receptors, reducing LDL clearance. Current PCSK9 inhibitors (Repatha, Praluent) are injectable monoclonal antibodies requiring monthly or biweekly dosing indefinitely at $500-700/month. A single-dose CRISPR epigenetic PCSK9 silencer would eliminate lifetime injection burden and drug cost, representing a transformative advance for cardiovascular disease prevention. The LDL-cardiovascular disease prevention market exceeds $10B annually.

### What delivery approach does Scribe use for liver-targeted gene silencing?
Scribe uses lipid nanoparticles (LNPs) — the same delivery technology proven in COVID-19 mRNA vaccines — to deliver its CRISPR epigenetic silencing constructs to the liver after IV infusion. LNPs naturally accumulate in the liver due to ApoE receptor-mediated uptake, making liver-targeting highly efficient. This validated delivery approach reduces one of the major risks of liver gene therapy — delivery uncertainty — allowing Scribe to focus development risk on the gene silencing mechanism itself.

### What is Scribe's competitive position in the gene silencing landscape?
Scribe competes with Intellia Therapeutics (CRISPR editing, PCSK9 and TTR programs), Beam Therapeutics (base editing), Verve Therapeutics (base editing for PCSK9 — in clinical trials), and Alnylam Pharmaceuticals (siRNA, inclisiran — approved annual PCSK9 siRNA). Scribe's epigenetic silencing approach offers potentially more durable silencing than siRNA (which degrades over months) and avoids DNA breaks of editing approaches — differentiating on safety and durability rather than competing head-to-head on mechanism.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*